Outputs & Policy Impact

Outputs & Policy Impact

 

Com-COV2

Letter

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum (The Lancet)

More

Paper

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (The Lancet) More
Policy Impact

WHO : Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19 (WHO iris)

More

 

COV-Boost

Paper Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (The Lancet) More

Policy

Impact

JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022  (Gov.uk) More
Policy Impact

WHO : Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19 (WHO iris)

More

 

ComFluCOV

Paper

Safety and Immunogenicity of Concomitant Administration of COVID-19 Vaccines with Seasonal Influenza Vaccines (The Lancet)

More

Policy

Impact

JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022 (Gov.uk) More

Policy

Impact

JCVI interim advice: potential COVID-19 booster vaccine programme winter 2021 to 2022 (Gov.uk) More
 

Com-COV

Paper

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data (The Lancet)

More

Paper

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (The Lancet)

More

 

What's the STORY

Policy Impact What’s the STORY results presented to UK SAGE More

 

Output Details

From the guidance :

"However, the available evidence on NVX-CoV2373 in the context of heterologous usage is currently limited to two studies assessing the use of NVX-Cov2373 as a second or booster dose (8, 9).

8. Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet. doi: 10.1016/S0140-6736(21)02717-3.

9. Stuart ASV, Shaw RH, Liu X, Greenland M, Aley PK, Andrews NJ et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2021. doi: 10.1016/S0140-6736(21)02718-5."

 

Read Now (WHO iris)

 

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

Data published in December 2021 from the COMCOV2 study relates to the Omicron variant of concern and have been presented in a letter. These data show that immune system antibody responses (neutralising antibodies) against the Omicron variant are lower in people who have had two doses of Oxford/AstraZeneca than two doses of Pfizer COVID-19 vaccine.

Read Now (The Lancet)

 

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK

The results of this study show multiple vaccines are appropriate to complete primary immunisation following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification.

Read Now (The Lancet)

 

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK

Six different COVID-19 boosters are safe and provoke strong immune responses in people who have previously received a two-dose course of ChAdOx1-nCov19 (Oxford–AstraZeneca [ChAd]) or BNT162b2 (Pfizer-BioNTech [BNT]), according to the first randomised trial of boosters given after two doses of either vaccine, published in The Lancet.

Read Now (The Lancet)

 

JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022

The JVCI recommendations to Government regarding booster vaccinations, which have been accepted as part of the government's Covid Autumn and Winter Plan, draw heavily on the ouputs from these two NISEC studies.

Read Now (Gov.uk)

 

Safety and Immunogenicity of Concomitant Administration of COVID-19 Vaccines with Seasonal Influenza Vaccines

The results of ComFluCOV have shown it is safe for people to be vaccinated against COVID-19 and influenza at the same time. The results of this study have been presented to the JCVI to aid policy makers in planning vaccination programmes.

Read Now (The Lancet)

 

Com-COV Results

The results from these studies are directly informing the use of ‘Mix and ‘Match’ COVID-19 vaccine schedules in the UK and globally. These results have shown that receiving mixed schedules of the ChAdOx1 nCOV-19 (‘Oxford AstraZeneca’) and BNT62b2 (Pfizer) vaccines administered at a 4 week interval generates higher antibodies and T cells against the COVID-19 virus than two doses of the ChadOx1 nCOV-19 vaccine. We also found that these mixed schedules resulted in a greater frequency of short terms side effects such as fatigue and feverishness. Initial results are available at:
 

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data (The Lancet)

 
and
 

Safety and Immunogenicity Report from the Com-COV Study (The Lancet)

 
These results have informed use of mixed schedules in the UK and internationally, demonstrating that the ChAdOx1 nCOV-19 followed by BNT62b2 may be appropriate according to local and individual circumstances.

 

JCVI interim advice: potential COVID-19 booster vaccine programme winter 2021 to 2022

ComFluCOV, led by Dr Rajeka Lazarus at University Hospitals Bristol and Weston NHS Foundation Trust, is evaluating the co-administration of COVID-19 and influenza vaccines and has directly informed the planned implementation of the 2021/2022 influenza and COVID-19 booster campaigns.

Read More (GOV.UK)

 
What’s the STORY

This study has collected over 3500 blood samples from nearly 3000 children, adolescents and young adults from November 2019 to June 2021. Initially designed to evaluate the concentrations of antibodies against vaccine preventable diseases such as diphtheria and group C meningococcus (MenC) in 0 to 24 year olds across England, this was adapted in response to the COVID-19 outbreak to conduct a unique, community based assessment of SARs-CoV-2 infection and immunity throughout the pandemic. These results have been presented to UK SAGE to inform policy regarding re-opening of schools and risk factors for infections.